YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

In Vitro Antibacterial Activities of CRB 529, 535, 538, 545 and 550, A New Carbapenem Derivatives

신규 Carbapenem 유도체 CRB 529, 535, 538, 545, 550의 시험관내 항균력 평가

  • 민관기 (㈜종근당 중앙연구소 약리 독성 연구실) ;
  • 김준겸 (㈜종근당 중앙연구소 약리 독성 연구실) ;
  • 이홍우 (㈜종근당 중앙연구소 약리 독성 연구실) ;
  • 김정우 (㈜종근당 중앙연구소 약리 독성 연구실)
  • Published : 1995.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

The in vitro antibacterial activities of new carbapenem. CRB 529, 535, 538, 545 and 550 with meropenem and imipenem were compared. CRB 529. 535, 538, 545 and 550 proved to have a broad an tibacterial spectrum. Its in vitro activity against standard 20 strains was almost the same as that of imipenem and slightly higher than that of meropenem. However. against clinical isolated P. aeruginosa, CRB 529, 535, 538, 545 and 550 showed significantly higher activity than imipenem, and also CRB 529, 535, 538, 545 and 550 showed almost the same activity than imipenem and meropenem against 82 clinical isolated strains including S. aureus (MRSA), S. aureus (MSSA), E. faecalis, E. facium, E. coli, P. aeruginosa, K. pneumonia, P. mirabiris, P. stuartii, M. morganii, C. freundii, E. cloacae, S. marcescens and A. calcoaceticus var. anitratus. The stability of CRB 529, 535, 538, 545 and 550 against porcine renal dehydropeptidase-I(DHP-1) was 10 folds higher than that of imipenem and was 3 folds higher than that of meropenem.

Keywords

References

  1. Chemother. v.33 Studies on immunogenecity of imipenem, a carbapenem and cilastatin sodium a specific competitive inhibitor of dehydropeptidase-1 Maki,E.;Kudo,M.;Yoshida,T.
  2. Chemother. v.40 In vitro and in vivo activities of a new carbapenem, meropenem Goto,S.;Miyazaki,S.;Kaneko,Y.
  3. Chemother. v.40 In vitro antibacterial activity of meropenem, a new carbapenem antibiotic Sumita,Y.;Mitsuhashi,S.
  4. Chemother. v.40 Meropenem its in vitro antibacterial activity and biological stability Yokota,T.;Suzuki,E.;Arai,K.
  5. Chemother. v.40 Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals Sumita,Y.;Nouda,H.;Tada,E.;Kohzuki,T.;Kato,M.;Okuda,T.;Fukasawa,M.
  6. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. F-1 Antibacterial activity of a new carbapenem BO2727 and its stability to β-lactamases Inoue,K.;Hamano,Y.;Mitsuhashi,S.
  7. 34th Interscience Conference on Antimicrobial Agents and Chemother, Abstract No. F-5 Evaluation of in vitro antimicrobial activity of BO2727, a novel carbapenem, against MRSA and coagulase negative staphylococci Suzuki,E.;Asada,K.;Hironatsu,K.
  8. 34th Interscience Conference on Antimicrobial Agents and Chemother, Abstract No. F-11 Antipseudomonal activity of BO2727 against imipenemand or meropenem resistant pseudomonas aeruginosa Hashizume,T.;Hazumi,N.;Shibata,K.;Tanaka,N.
  9. Antibiotics in Laboratory medicine(2nd ed.) Laboratory evaluation of new antibiotics in vitro and experimental animal infection Cleveland,R.;Grunberg,E.;Lorian,V.
  10. Biochem. Biophys. Acta v.522 Purification and properties of human kidney dihydropeptidases Sugiura,M.;Ito,Y.;Hirana,K.;Sawaki,S.
  11. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. F-31 Comparative study of biapenem(L627) and imipenem/cilastatin in complicated urinary tract infection Kawada,Y.
  12. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract No. F-29 Biapenem (L-627), A new carbapenem: pharmacokinetics and clinical evaluation in pediatric patients Fuji,R.;Nishimura,T.;Sunakawa,K.